Selective ROCK2 inhibitors ameliorate murine models of Multiple Sclerosis and demyelination by harnessing inflammation and restoring homeostasis.
What We Do
We are pioneering safe innovative and novel therapies for patients with fibrotic, autoimmune, and CNS diseases. We focus to alleviate disease while restoring homeostasis through multiple concerted molecular pathways.
Our Science20+
scientists and researchers
8
drug candidates in development
20+
patents filed

For Patients
Your health is our mission. With decades of expertise behind us, we’re at the forefront of developing novel therapies that make a real difference. Our team’s deep rooted knowledge fuels our commitment to pioneering research and bringing safe, effective treatments to you as swiftly as possible. We’re dedicated to transparency and results, ensuring every breakthrough is a beacon of hope for your healthier tomorrow.
For PatientsSelective ROCK2 inhibitors ameliorate murine models of Multiple Sclerosis and demyelination by harnessing inflammation and restoring homeostasis.
November 16, 2026
Graviton BioScience Announces New Preclinical Data Highlighting the Potential of Selective ROCK2 Inhibition in Multiple Sclerosis at Neuroscience 2026
November 16, 2026
Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia
November 03, 2026
Graviton BioScience and CinRx Pharma Form CinRock Pharma to Advance ROCK2-Targeted Therapies for Cardiovascular Disease
November 02, 2026